| CPC C07K 16/2809 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)] | 18 Claims |

|
1. A chimeric antigen receptor (CAR), comprising:
a transmembrane domain,
a co-stimulatory domain,
an intracellular signaling domain, and
a targeting moiety that comprises an antibody or a fragment thereof and that specifically binds to human and/or mouse T cell receptor (TCR) variable regions Vβ and/or fragments thereof,
wherein said antibody or a fragment comprises heavy chain complementary determining region 1-3 (HCDR1-3) and light chain complementary determining region 1-3 (LCDR1-3) and
the HCDR1 comprises the amino acid sequence of SEQ ID NO:67, the HCDR2 comprises the amino acid sequence of SEQ ID NO:68 and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 69,
the LCDR1 comprises the amino acid sequence in SEQ ID NO:64, the LCDR2 comprises the amino acid sequence in SEQ ID NO:65, and the LCDR3 comprises the amino acid sequence in SEQ ID NO:66.
|